Etidronic acid and its calciumcomprising complexes in the treatment of experimental osteoporosis in estrogendeficient rats
Systemic osteoporosis and its complications remain important medical and social problems which are associated with an increased risk of disability and mortality from their effects, i.e., low-trauma fractures. A great step forward in the study of the mechanisms of this disease and its treatment has been achieved in recent years, allowing novel agents that affect both the formation and resorption processes of bone tissue and effectively reduce the risk of vertebral and non-vertebral fractures to be discovered [1] [2] [3] .
The largest group of antiosteoporotic drugs are antiresorptive agents that affect the destruction (resorption) of bone; the main representatives are bisphosphonates-sodium or potassium salts of bisphosphonic acids [3] [4] [5] [6] . In recent years, a number of these compounds have been developed and are now used in the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and secondary osteoporosis, as well as for the prevention of bone metastases [6] [7] [8] [9] . Due to their affinity for hydroxyapatite (bone component), they can bind to bone mineral matrix and inhibit the activity of osteoclasts, the cells mainly responsible for bone destruction.
Etidronic acid (EA) or 1-hydroxyethane 1.1-diphosphonic acid is a bisphosphonate used in different technical and cosmetic fields as well as for pharmaceutical treatment. An etidronate is a salt of EA. It belongs to the first generation of bisphosphonates (as do clodronic and tiludronic acids), which don't include the nitrogen atom in their structure, and is metabolized intracellularly by osteoclasts to cytotoxic analogs of adenosine triphosphate. Bisphosphonates are absorbed by osteoclasts, where they break up the formation of cytoskeleton required for osteoclast attachment to the bone and reduce the secretion of these cells' lysosomal enzymes [3, 4, 10] . However, the mechanism of bisphosphonate action is not yet completely understood.
On the one hand, EA is an accessible and cheap bisphosphonate. On the other hand, the data about its positive effects on bone are mixed. Some studies confirmed a negative effect on bone formation in cases of prolonged application, so authors recommend its prescription in intermittent courses [3, 5, 10] .
After the appearance of the second generation of bisphosphonates (nitrogen-containing compounds), etidronate (Xydifon ® ; Didronel ® , Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA) is nowadays less often prescribed for the treatment of postmenopausal and senile osteoporosis; however, it continues to be used in patients with secondary osteoporosis and a high level of calcium in the blood (especially malignant tumors, Paget's disease, and for the prevention and treatment of ectopic ossification).
According to numerous studies, bisphosphonates not only have antiresorptive activity, but they also have an inhibitory effect on the bone mineralization process; consequently, in the treatment of systemic osteoporosis today, all bisphosphonates are administered with sufficient consumption of calcium and vitamin D (1000 mg/d and 400-800 IU/d, respectively) [1] [2] [3] . This forms the grounds to investigate the therapeutic efficacy of soluble complexes of bisphosphonic acid with calcium. The combination of bisphosphonic acid with calcium in one complex compound provided the prerequisites to expect the antiresorptive action (due to the presence of bisphosphonic acid) and a positive effect of calcium (which affects the bone remodeling process, including its mineralization).
Conjoint use of bisphosphonates with calcium and vitamin D (Ca/D) is essential for the treatment of postmenopausal osteoporosis; however, compliance with such therapy is often low. The combination of bisphosphonates, calcium, and vitamin D in one prescription could poten- tially influence adherence to treatment. In addition, there is currently a great need to develop new compounds of bisphosphonic acids, including etidronate, which are more effective and cheaper. The aim of this study was to investigate the composition, stability, and biological activity of the complexes that are formed in solution upon interaction of calcium ions with EA, and to compare their effects on bone mineral density (BMD) indices in estrogen-deficient female Wistar rats with experimental osteoporosis.
Materials and methods
EA is a tetrabasic acid (Н4L) containing two phosphonic and one hydroxyl group. In a preliminary study on the interaction of calcium and EA, we found that three complexes ([CaHL] -, [CaL] 2-, and [Ca2L]; . Fig. 1 ) are formed in the diluted solutions at a Ca 2+ :EA ratio of 1:1 (. Fig. 1 ).
This experimental study was performed at the D. F. Chebotarev Institute of Gerontology of NAMS, Ukraine, and was conducted according to the rules of the European Convention for the humane treatment of animals [11] . Forty 40 reproductive [12] female Wistar rats (four groups, 10 animals in each group) were included in the study. The age of the rats at the time of study enrollment was 4 months; body weight (mean, M ± standard deviation, SD) was 190 ± 10 g. The rats existed in the experimental department of the institute under natural light and a standard diet, with free access to food (standard granulated feed concentrate) and water.
Systemic postmenopausal osteoporosis was modeled by bilateral oophorectomy with fixed ether anesthesia. Osteoporosis treatment was started 4 months after surgery. The animals were divided into four groups depending on the type of treatment: the first group did not receive any treatment, only supplementation of To investigate the therapeutic effects of EA and its complexes with calcium, solutions containing EA and CaCl2 in an equimolar ratio (1:1) were prepared. For the approximate value of LD50, LD50 of Mebifon drug (salt of methylene bisphosphonic disodium acid) was used. We applied the dose of~160 mg/kg in rats for intraperitoneal administration. Based on the average weight of the rats at the start of therapy, i.e., 190 ± 10 g, the dose of studied agents for one rat was 0.75 mg. The tested solution had an EA concentration of 0.75 mg/ml (3.35 × 10 -3 mol/L) and an equimolar (3.35 × 10 -3 mol/L) concentration of CaCl2. We used saline as the solvent.
All tested solutions containing EA and its calcium complexes were injected intraperitoneally under sterile conditions. In the relevant groups, Ca/D was added to the diet during the 3-month observation period starting from the date of the start of treatment in all groups.
In vivo assessment of bone parameters was performed using dual-energy X-ray absorptiometry (DXA) with Prodigy (GE Medical systems, Model 8743, 2005; USA; program "Experimental animals"), which allows measurement of bone mineral density (BMD) and bone mineral content (BMC) in different parts of the skeleton in small animals. We measured these parameters in spine and total body. Measurement was performed thrice (before treatment, after 1 and 3 months of observation) with fixation of the animal using a special device and ether anesthesia. BMD and BMC indices in studied regions of the rats' skeleton were not significantly different between the groups before treatment. BMD measurement error using the DXA was ±0.01 g/cm 2 . Statistical analysis was performed using the software package Statistisa 6.0© (StatSoft. Inc.). We used the following methods of statistical analysis: comparing means (M) were calculated by Student's t-test for independent groups, evaluation of parameter dynamics in group were counted by Student's t-test for depended samples. Data are presented as M ± SD. The critical level of significance for statistical hypotheses testing was considered to be p < 0.05.
Results
In soluble complexes of 1:1, EA was coordinated to the calcium ion bidentally by two oxygen atoms into two phosphonic groups for closure of the six-membered chelate ring. In the first complex, [Ca2L], another calcium ion closes the second sixmembered ring. Using published data [13] , we constructed the distribution diagram of the equilibrium concentrations of complexes with different compositions as a function of pH in the system with CaCl2:EA = 1:1 (. Fig. 2 . 7H2O were isolated from aqueous solutions.
Analysis of BMD indices in female rats which received only Ca/D supplementation after bilateral oophorectomy did not reveal positive dynamics in the spine or total body after 1 and 3 months of observation (. Tables 1 and 2 ). The combined treatment with EA and additional supplementation of Ca/D did not show any significant differences in BMD indices of the spine and total body after 1 month of follow-up. Also, we did not find any reliable changes in BMD index of the spine (sBMD) after 3 months of observation. However, significant differences were found in the total body BMD parameters (tbBMD) of the rats after 3 months of therapy (t = 3.64, p = 0.005; . Tables 1 and 2) .
Analysis of DXA indices in female rats that received the soluble Ca-EA complex of showed significant positive changes of sBMD at 1 and 3 months after its injection (sBMD dynamics Results. Therapy with EA and Ca/D showed significant differences in total body BMD (tbBMD) only after 3 months. We established reliable changes in spine BMD (sBMD) and tbBMD after 1 and 3 months of treatment in group 3 rats: administration of Ca-EA with Ca/D had positive effects on sBMD at 1 and 3 months, and on tbBMD after 3 months. We did not establish any significant changes between sBMD and tbBMD after 1 and 3 months of therapy dependent on additional Ca/D supplementation (groups 3 and 4). Conclusion. We showed a positive effect of the studied Ca-EA complexes on the BMD and BMC indices, with or without additional supplementation of Ca/D. More explicit dynamics of indices were observed in the group of animals treated with Ca-EA without additional Ca/D after 1 and 3 months of follow-up.
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Oophorectomy · Rats, Wistar · Calciumcomprising complexes of etidronic acid · Bone mineral density amount 0.009 ± 0.008 g/cm 2 , p = 0.02 and 0.014 ± 0.014 g/cm 2 , p = 0.01, respectively; . Table 1 ). The positive impact of Ca-EA was also confirmed in tbBMD after 1 and 3 months follow-up (. Table 2 ). It should be noted that this positive trend was found in animals without any additional daily administration of Ca/D.
The administration of Ca-EA combined with Ca/D supplementation also has positive effects on sBMD after 1 or 3 months follow-up (sBMD dynamics amounted to 0.009 ± 0.008 g/cm 2 , p = 0.02 and 0.009 ± 0.010 g/cm 2 , p = 0.05, respectively; . Table 1 ). However, we did not find significant positive changes of tbBMD index after 1 month of observation. Significant positive dynamics of tbBMD index were established only after 3 months of follow-up. Furthermore, we did not establish any significant changes between BMD parameters after 1 and 3 months of observation in dependence on additional Ca/D supplementation in female rats which received Ca-EA (groups III and IV; . Tables 1 and 2) .
Analysis of BMC indices of the spine in female rats after bilateral oophorectomy did not show any dynamics dependent on the type of treatment at the 1-and 3-month follow-ups (. Table 3 ). Nevertheless, it was established that there is a positive tendency in total body BMC dynamics after 1 month of follow-up in rats that received Ca/D supplementation alone and a significant difference after 3 months of observation (BMC dynamics amounted to 1.02 ± 1.10 g, t = 2.45, p = 0.05). However, we did not find any reliable differences in the total body BMC indices in rats with experimental osteoporosis which received EA in combination with Ca/D supplementation after 1 or 3 months of follow-up (. Table 4) .
Therapy with the Ca-EA complex without additional administration of Ca/D led to a significant increase of Table 4 ). This effect was maintained after 3 months of follow-up (dynamics amounted to 1.05 ± 0.88 g, р = 0.004). In the fourth group (Ca-EA + Ca/D) we did not find the positive change in BMC index after 1 month of observation; however, it was present after 3 months of follow-up.
Discussion
According to a number of literature publications [3] [4] [5] [6] [7] [8] [9] , bisphosphonates are the largest class of antiresorptive agents which are widely used in clinical practice. Nowadays, there are different generations of bisphosphonates with various types of prescription (daily, monthly, once a year, etc.). For treatment of osteoporosis, all bisphosphonates are administered with sufficient consumption of calcium and vitamin D (1000 mg/d and 400-800 IU/d, respectively) [1] [2] [3] . This forms the grounds to investigate the therapeutic efficacy of soluble complexes of bisphosphonic acid with calcium. New bisphosphonic acids have been found during recent years [14] [15] [16] ; nevertheless, there is a great need to develop new compounds of bisphosphonic acids, including ones from different generations (e.g., etidronate). The purpose of our study was to investigate the composition, stability, and biological activity of the complexes that are formed in solution upon the interaction of calcium ions with etidronic acid, and to compare their effects on bone mineral density indices in estrogen-deficient female rats with experimental osteoporosis.
Nowadays, DXA is an established gold standard in the assessment of bone state. According to existing literature data [3, 12] , BMD is an integral index of bone strength and reflects the ratio between BMC and its area. Therefore, its measurement is extremely important in the assessment of bone state. As the main bone loss in persons with systemic osteoporosis prevails in spongy bone tissue, it is highly essential to measure not only the dynamics of the total body, but also of the spine in particular.
The performed analysis of BMD indices in female rats which received only Ca/D supplementation after bilateral oophorectomy did not reveal positive dynamics in the spine or total body after 1 and 3 months of observation, confirming the literature data [1] [2] [3] about the small and insufficient efficacy of Ca/D only for the treatment of postmenopausal osteoporosis.
The combined therapy with EA and additional supplementation of Ca/D did not establish any significant changes in BMD indices of the spine and total body after 1 month of follow-up. Also, we did not find any reliable effect on sBMD after 3 months of observation. The positive changes were present in tbBMD after 3 months of therapy, which confirms the literature data [3, 10] about the moderate efficacy of etidronate in the treatment of osteoporosis.
Analysis of DXA indices in female rats that received the soluble calcium complex of EA with Ca/D has established significant differences in spine and tbBMD indices 1 and 3 months after its injection. It should be noted that this positive trend was found in animals without any additional daily administration of Ca/D, which is essential for the treatment of osteoporosis and has important clinical significance.
The administration of Ca-EA complex combined with Ca/D supplementation also has positive effects on sBMD after 1 or3 months offollow-up; however, we did not find the significant positive changes of tbBMD after 1 month of observation. This positive significant effect of tbBMD was shown only after 3 months of follow-up. It is very important, however, that we did not establish any significant changes between BMD parameters after 1 and 3 months of treatment in dependence on additional Ca/D supplementation in female rats which received Ca-EA complex-a fact which could be of clinical importance.
As the discussions on the possible negative impact of bisphosphonates and, in particular, EA on bone mineralization are ongoing, we performed the analyses of BMC indices to allow evaluation of bone mineralization under the influence of various factors, including our studied compounds. Analysis of spine BMC indexes of female rats after bilateral oophorectomy did not show any dynamics after 1 and 3 months follow-up depend on the type of therapy, which does not support the theory that these treatment regimens have negative effects on bone mineralization in the spine within these treatment durations.
Furthermore, a positive tendency in BMC dynamics was shown after 1 month of observation in female rats that received Ca/D supplementation alone after bilateral oophorectomy, and a significant difference after 3 months of observation. However, we did not find any reliable differences in the total body BMC indices in female rats with experimental osteoporosis which received EA in combination with Ca/D supplementation after 1 or 3 months follow-up.
Nevertheless, administration of Ca-EA complex without additional use of Ca/D leads to a significant increase of total bodyBMC indices after1 and 3 months of treatment, while in the group that received this complex with additional administration of Ca/D, we did not find the positive change in BMC index after 1 month of observation; however, it was also present after 3 months of follow-up.
Our study is the first to explore calcium complexes of etidronic acid in the treatment of postmenopausal osteoporosis, so further research is needed to confirm these results.
The limitations of this study are the small groups and only two time points (1 and 3 months after treatment). In addition, the investigations of some biochemical markers of bone metabolism and histological studies will be valuable in the future. 
Conclusion

